Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 10/25 10:00:28 pm
113.96 USD   +0.31%
12:01p JOHNSON & JOHNS : Research Reports on Drug Makers Equities -- Pfizer..
10/24 JOHNSON & JOHNS : Hepatitis B Virus Market (HBV) Review with 2016-20..
10/24 JOHNSON & JOHNS : Davenport Co buys $162,560,871 stake in Johnson & ..
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Johnson & Johnson : Research Reports on Drug Makers Equities -- Pfizer, Merck, AbbVie, and Johnson & Johnson

share with twitter share with LinkedIn share with facebook
share via e-mail
10/26/2016 | 12:01pm CEST

NEW YORK, October 26, 2016 /PRNewswire/ --

Stock-Callers.com is closely reviewing the most recent performances of four major players in the Drug Manufacturers space: Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). These companies belong to the Healthcare sector which was little changed from its mid-day declines on Tuesday, October 25, 2016, with the NYSE Health Care Index slipping about 0.5%, and shares of health care companies in the S&P 500 declining 0.2% as a group. Learn more about these stocks by accessing their free research reports at:



New York headquartered Pfizer Inc.'s shares rose 0.47% and finished Tuesday's trading session at $32.28. A total volume of 19.32 million shares was traded, which was above their three months average volume of 18.96 million shares. Since the start of this year, the stock has advanced 2.76%. The Company's shares are trading below their 200-day moving average by 1.43%. Moreover, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 32.20.

On October 13th, 2016, research firm Jefferies downgraded the Company's stock rating from 'Buy' to 'Hold'.

On October 21st, 2016, Astellas Pharma Inc. and Pfizer announced the U.S. Food and Drug Administration approved a supplemental New Drug Application to update the U.S. product labeling for XTANDI(R) (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer who were treated with enzalutamide compared to patients who were treated with bicalutamide. Free research report on PFE is available at:

http://stock-callers.com/registration/?symbol=PFE Merck  

On Tuesday, shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. recorded a trading volume of 15.12 million shares, which was above their three months average volume of 10.25 million shares. The stock ended the session 1.98% higher at $61.95. The Company's shares have gained 6.49% in the previous three months and 20.15% on an YTD basis. The stock is trading 10.39% above its 200-day moving average. Furthermore, shares of Merck, which provides health care solutions worldwide, have an RSI of 48.91.

On October 13th, 2016, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Neutral' to 'Buy'.

On October 25th, 2016, Merck reported that worldwide sales were $10.5 billion for Q3 2016, an increase of 5% compared with Q3 2015, including a 1% negative impact from foreign exchange. For Q3 2016, GAAP EPS assuming dilution were $0.78 compared to EPS of $0.64 in Q3 2015. Q3 2016 pharmaceutical sales increased 6% to $9.4 billion. The complimentary research report on MRK can be downloaded at:

http://stock-callers.com/registration/?symbol=MRK AbbVie  

Shares in Illinois-based AbbVie Inc. closed the day at $61.55, up 0.70%. The stock recorded a trading volume of 6.41 million shares, which was higher than its three months average volume of 6.16 million shares. The Company's shares have gained 7.92% on an YTD basis, and are trading 3.07% above their 200-day moving average. Additionally, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 45.56.

On October 18th, 2016, research firm Leerink Partners initiated a 'Market Perform' rating on the Company's stock, issuing a target price of $70 per share.

On October 19th, 2016, AbbVie in cooperation with Neurocrine Biosciences, Inc. announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis. The data demonstrate that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain and non-menstrual pelvic pain associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale. Visit us today and access our complete research report on ABBV at:

http://stock-callers.com/registration/?symbol=ABBV Johnson & Johnson  

At the closing bell yesterday, shares in New Brunswick, New Jersey-based Johnson & Johnson ended 0.31% higher at $113.96 and with a total trading volume of 5.59 million shares. The stock has advanced 13.29% since the start of this year. The Company's shares are trading above their 200-day moving average by 1.18%. Furthermore, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 34.94.

On October 19th, 2016, research firm UBS reiterated a 'Buy' rating on the Company's stock with an increase of the target price from $137 a share to $144 a share.

On October 20th, 2016, Johnson & Johnson' Board of Directors declared a cash dividend for Q4 2016 of $0.80 per share. The dividend is payable on December 6th, 2016 to shareholders of record at the close of business on November 22nd, 2016. Get free access to your research report on JNJ at:



Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        Email: info@stock-callers.com 
        Phone number: +44 330 808 3765 
        Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2


CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
12:01p JOHNSON & JOHNSON : Research Reports on Drug Makers Equities -- Pfizer, Merck, A..
10/24 JOHNSON & JOHNSON : Hepatitis B Virus Market (HBV) Review with 2016-2025 Forecas..
10/24 JOHNSON & JOHNSON : Davenport Co buys $162,560,871 stake in Johnson & Johnson
10/24 JOHNSON & JOHNSON : As achievement gap widens, Phoenixville schools seek ways to..
10/22 JOHNSON & JOHNSON : to buy wind power in the US
10/22 JOHNSON & JOHNSON : Carlton Hofferkamp Jenks Wealth Management buys $2,342,903 s..
10/21 JOHNSON & JOHNSON : U.s. fda approves vermox chewable (mebendazole) for treatmen..
10/21 JOHNSON & JOHNSON : E.ON inks 100MW wind power deal with Johnson & Johnson
10/20 JOHNSON & JOHNSON : Announces Quarterly Dividend for Fourth Quarter 2016
10/20 JOHNSON & JOHNSON : Findings from Johnson & Johnson Broaden Understanding of Imm..
More news
Sector news : Pharmaceuticals - NEC
09:08a Bayer third-quarter profit beats forecasts on pharma, pesticides
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
10/25 ChemChina ready for concessions to clinch delayed Syngenta deal in 2017 - sou..
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06:31a Pharma Momentum Builds For Johnson & Johnson
10/25 My Dividend Growth Portfolio - Q3 2016 Summary
10/24 CA INC. : Good Total Return, But Is The Company Ready To Grow Again?
10/24 My Income Portfolio Quarterly Update (Q3 2016)
10/24 JOHNSON & JOHNSON : Dark Pool Indicator Flashes Warning
Financials ($)
Sales 2016 72 067 M
EBIT 2016 22 026 M
Net income 2016 16 255 M
Finance 2016 19 430 M
Yield 2016 2,76%
P/E ratio 2016 19,18
P/E ratio 2017 16,98
EV / Sales 2016 4,06x
EV / Sales 2017 3,78x
Capitalization 311 781 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.94%311 781
ROCHE HOLDING LTD.-16.53%198 222
PFIZER INC.0.00%195 799
NOVARTIS AG-14.06%191 921
MERCK & CO., INC.17.29%171 305
More Results